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the Management of Acute Ischemic Stroke*
Leonardo Rangel-Castilla, MD,y L. Nelson Hopkins, MDzI n the paper by Marmagkiolis et al. (1) in this issueof JACC: Cardiovascular Interventions, the au-thors performed a search and meta-analysis to
identify randomized, controlled trials (RCTs) in which
stent retrievers were used for acute ischemic stroke
management using the terms “endovascular therapy
and ischemic stroke,” “intra-arterial therapy and
ischemic stroke,” and “randomized controlled trials.”SEE PAGE 1758Data elements included the National Institutes of
Health Stroke Scale score, use of intravenous tissue
plasminogen activator (t-PA), history of diabetes and
atrial ﬁbrillation, 90-day modiﬁed Rankin Scale
(mRS) score, symptomatic intracranial hemorrhage
(ICH), and 90-day mortality. The primary endpoints
included “functional independence” (deﬁned as a
low 90-day mRS score of 0–2), symptomatic ICH,
and 90-day mortality. The meta-analysis included*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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and standard therapy (ST) for acute stroke; these
were MR CLEAN (Multicenter Randomized Clinical
Trial of Endovascular Treatment of Acute Ischemic
Stroke in the Netherlands) (2), REVASCAT (Random-
ized Trial of Revascularization with Solitaire FR De-
vice vs Best Medical Therapy in the Treatment of
Acute Stroke Due to Anterior Circulation Large Vessel
Occlusion Presenting within Eight Hours of Symptom
Onset (3), EXTEND IA (Extending the Time for
Thrombolysis in Emergency Neurological Deﬁcits–
Intra-arterial) (4), SWIFT PRIME (Solitaire With the
Intention For Thrombectomy as PRIMary Endovascu-
lar treatment) (5), and ESCAPE (Endovascular Treat-
ment for Small Core and Anterior Circulation
Proximal Occlusion with Emphasis on Minimizing
CT to Recanalization Times) (6), comprising 500,
196, 70, 315, and 206 patients, respectively. A total
of 634 patients were included in the ET (intervention)
group and 653 patients in the ST (control) group. The
frequency of a low 90-day mRS score (0 to 2) in the
intervention group was 42.6% compared with 26.1%
in the control group (odds ratio: 2.43, 95% conﬁdence
interval: 1.9 to 3.09; p < 0.0001). The frequency of
intracranial bleeding was 4.2% in the ET group
compared with 4.3% in the ST group (relative risk:
1.08, 95% conﬁdence interval: 0.64 to 1.82; p ¼ 0.78);
90-day mortality was 15.1% in the ET group compared
with 18.7% in the ST group (relative risk: 0.81, 95%
conﬁdence interval; p ¼ 0.19). This meta-analysis
demonstrates the remarkable safety and efﬁcacy of
endovascular treatment in improving outcomes. It
also conﬁrms the effectiveness of endovascular treat-
ment for acute ischemic stroke due to large-vessel
occlusion in an extended time window (12 h).
Time is a crucial and important factor. In MR
CLEAN, obtaining vascular imaging studies (e.g.,
computed tomography angiography and magnetic
resonance angiography) would delay the initiation
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1767of treatment and affect outcome; therefore, this
vascular imaging was not obtained, resulting in the
enrollment of many patients who lacked large-vessel
occlusions. Patients enrolled in MR CLEAN, EXTEND-
IA, ESCAPE, and SWIFT PRIME underwent radio-
graphic evaluation for t-PA therapy eligibility and ET
in parallel, rather than sequentially, to save time.
t-PA was given without delay in the ET group. Median
times from symptom onset to groin puncture were
260, 210, 185, 224, and 269 min in the MR CLEAN,
EXTEND-IA, ESCAPE, SWIFT PRIME, and REVASCAT
trials, respectively. These studies demonstrate that
obtaining diagnostic imaging does not delay the
initiation of t-PA therapy.
Regarding safety, a major concern is that patients
may be at risk of ICH after endovascular recanalization
therapy. We may deduce that higher rates of recana-
lization after ET come at the expense of a higher rate of
hemorrhage; however, this was not observed in any of
the RCTs. The rates of symptomatic ICH in the endo-
vascular groups ranged from 0% to 7.7% and were not
different from those for the IV t-PA–alone group.
Mortality was similar in both groups across studies.In all these studies, patients achieved signiﬁcantly
increased rates of recanalization and functional
outcomes, without increasing the risk of symptomatic
ICH or death. We previously reported that decreased
cerebral blood volume in the basal ganglia may be
associated with the risk of hemorrhagic conversion
after recanalization and reperfusion (7).
In summary, ET for acute ischemic stroke has
changed remarkably over the past decade. Endo-
vascular strategies have evolved from aspiration to
retrievable stents. With the recent publication of
these 5 RCTs, mechanical thrombectomy, when used
in combination with intravenous t-PA, has demon-
strated a signiﬁcant radiographic and clinical beneﬁt
over traditional strategies with intravenous t-PA
alone. These results have placed ET at the forefront of
stroke treatment, redeﬁning the standard of care.
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